"Empowering Cancer Care Through Compassion, Innovation, and Expertise."
At BBMCT, we are dedicated to advancing the fight against cancer through comprehensive, patient-centered care at AIIMS Hospital. Our specialized programs cover a wide range of oncology indications, including breast, lung, prostate, colorectal, and ovarian cancers. With a commitment to innovation and excellence, our multidisciplinary team of experts collaborates to deliver cutting-edge treatments tailored to each patient’s unique needs. We understand that a cancer diagnosis can be overwhelming, which is why we prioritize compassionate support alongside our medical expertise. From early detection and diagnosis to personalized treatment plans and ongoing care, we are here to guide you every step of the way. Our state-of-the-art facilities and research-driven approach ensure that you receive the most effective therapies available, all within a supportive environment.
At BBMCT, we believe in empowering our patients through education, advocacy, and community engagement, fostering hope and resilience in the face of adversity. Together, we strive to improve outcomes and enhance the quality of life for every individual affected by cancer. Choose BBMCT at AIIMS Hospital—where your health and well-being are our top priorities, and where hope meets healing. Join us in the fight against cancer today.
"BBMCT: Your partner in efficient, cost-saving clinical trial management."
“BBMCT is your trusted partner in navigating the complexities of clinical trials. Our commitment to efficient planning and execution sets us apart, ensuring that your projects stay on track and within budget. By streamlining processes and leveraging our expertise, we help clients save millions in development costs. With BBMCT, you gain a collaborative ally dedicated to advancing innovative healthcare solutions while maximizing your investment. Together, we can transform challenges into successful outcomes in the world of clinical research.”
- Immunotherapies (including checkpoint inhibitors, cancer vaccines, CAR-T cell therapies, bispecific antibodies and cytokines)
- Radiopharmaceuticals (in diagnostic and therapeutic setting)
- Cancer supportive care medications (in cytopenias, nausea/vomiting, mucositis, fungal infections)
- Early phase studies including basket/umbrella designs
Patient populations
Biosimilars in Oncology
Novel Target Therapies
Valued Sites Network
BBMCT: Leading The Way In Innovative Immuno-Oncology Clinical Trials
“BBMCT boasts a strong track record in managing studies of checkpoint inhibitors and other immuno-oncology agents. Breakthrough therapies are now identified earlier, with some receiving approval from combined phase I/II trials. Increasingly, we see new targeted therapies explored for multiple tumor types and in various combination regimens.”